TNFSF10 and neoplasm: To overcome tumor resistance to TRAIL, various therapeutic agents are used in combination with recombinant TRAIL or TRAIL receptor agonist mAbs and have shown to be effective in enhancing TRAIL efficacy against tumor cells [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27].